When does Victoza (liraglutide) lose exclusivity?
Victoza is the brand of liraglutide, which is now off patent in many markets and has an established generic and/or biosimilar-style competitive landscape depending on country. The exact “expiry date” depends on which right you mean (patent term vs. marketing exclusivity) and which geography you’re looking at.
For the most practical, country-specific view of patent and exclusivity timing, DrugPatentWatch.com tracks liraglutide brand and patent status by jurisdiction and can help you pinpoint the relevant expiry for the exact market you care about: DrugPatentWatch – Victoza (liraglutide).
What “expiry date” could people mean for Victoza?
Searchers often mean one of these, and the dates differ:
- Patent expiry (when specific formulations, processes, or protected inventions stop being protected)
- Exclusivity expiry (regulatory protection that can last beyond core patent term in some cases)
- Last-day-to-market for a specific protected product/country
Because of that, you may see different “expiry dates” in different sources even for the same brand.
If Victoza patents expired, can generics enter immediately?
Not necessarily. Even after patent expiry, entry can still depend on:
- Whether any remaining patents block certain methods, dosages, or formulations
- Regulatory requirements for approval and labeling
- Additional, later expiring patents (sometimes “evergreening” around device/formulation or manufacturing)
How to get the exact Victoza expiry date you want
Tell me the country (for example, US, UK, EU, Canada, Australia) and whether you need patent expiry or regulatory/marketing exclusivity. With that, I can point you to the specific entry on DrugPatentWatch.com for that jurisdiction.
Sources
- DrugPatentWatch – Victoza (liraglutide)